Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer

Clark, Joseph I.; Kancharla, Kiran; Qamar, Rubina; Fisher, Susan G.; Hantel, Alexander; Panganiban, Joy; Millbrandt, Linda; Albain, Kathy S.

doi:10.1016/s0169-5002(01)00251-3

Cited by 22 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Largely, these continued suboptimal results in advanced NSCLC can be attributed to chemotherapy resistance. Strategies aimed at preventing the development of resistant cells have been developed [11,12,13,14,15]. …”

Section: Introductionmentioning

confidence: 99%

“…Sequential regimens permit the use of several active and putatively non-cross-resistant drugs at maximum doses. The hypothesis for this approach is that mechanisms of tumor resistance to a given combination of cytotoxic drugs is circumvented, and the cumulative toxicity associated with the simultaneous administration of more than two drugs, without any dose reduction, is avoided [11,12,13,14,15,16,17,18,19,20,21,22]. …”

Section: Introductionmentioning

confidence: 99%

“…Based on the proven efficacy of docetaxel in NSCLC, both in first- as well as second-line (platinum failures) chemotherapy [7, 8, 12, 14,16,17,18,19, 23], and the efficacy and tolerability of the gemcitabine-carboplatin doublet [24, 25], we tested them sequentially, applying the ‘worst drug’ rule (Day hypothesis) [26] with an intent to determine if there is increased efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

et al. 2005

View full text Add to dashboard Cite

Rationale: Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival. Objectives: To assess the safety and efficacy of a novel sequential and putatively non-cross-resistant chemotherapy regimen. Methods: Eligibility included: stages IV and IIIB (malignant pleural effusion), performance status 0–1, and adequate renal, hepatic and bone marrow function. Patients with previously treated and controlled brain metastases were not excluded. Responses were determined according to the Response Evaluation Criteria in Solid Tumors. Treatment consisted of gemcitabine, 1,000 mg/m², on days 1 and 8, and carboplatin, AUC = 5, on day 1 every 4 weeks (2–4 cycles) followed by docetaxel, 75 mg/m², on day 1 every 3 weeks (4 cycles). Docetaxel was given after four cycles of gemcitabine-carboplatin or if progression of disease occurred, after the first two cycles. Results: Forty patients were enrolled. All patients received at least one cycle of gemcitabine-carboplatin. Due to PD, 15 patients received fewer than four cycles and only 1 received docetaxel subsequently. Of the 25 patients who completed four cycles of gemcitabine-carboplatin, 23 received docetaxel.In total, 24 patients received at least one cycle of docetaxel, and 12 patients completed four cycles of both regimens. The overall response rate was 23.6% (9/38 patients, 95% confidence interval, CI, 11–40%), with 15.8% (6/38 patients, 95% CI, 6–31%) and 12.5% (3/24 patients, 95% CI, 3–32%) response rates to gemcitabine-carboplatin and docetaxel, respectively. No patient with PD on gemcitabine-carboplatin responded to docetaxel. Toxicities were tolerable and mostly hematologic. Median survival time and progression-free survival were 6.7 and 4.9 months, respectively, with a 1-year survival of 37.5%. Conclusion: Sequential gemcitabine-carboplatin and docetaxel can be safely administered in advanced NSCLC. Our results are comparable to those achieved with other similar regimens and do not represent a significant improvement in the treatment of advanced NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Seu principal efeito adverso cardiovascular é a isquemia miocárdica secundária a vasoespasmo das artérias coronárias, que pode ocorrer tardiamente (entre dois e 11 dias) como no caso do vinorelbina ou algumas horas após a infusão, no caso da vincristina [207][208][209][210][211][212] . Também podem causar neuropatia autonômica 4 .…”

Section: -Alcaloides Da Vinca (Vincristina/vinblastina/ Vinorelbina)unclassified

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Filho¹,

Hajjar²,

Bacal³

et al. 2011

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

“…Several phase II trials have evaluated the activity and toxicity of a sequence of a combination regimen followed by a single agent [15][16][17][18][19][20][21][22]. Most of these treatments consisted of a platinum-based doublet followed by a taxane, either paclitaxel or docetaxel.…”

Section: A Doublet or A Triplet Followed By A Single Agentmentioning

confidence: 99%

Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature

Grossi¹,

Aita

Follador

et al. 2007

The Oncologist

View full text Add to dashboard Cite

LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the new chemotherapy design strategies (i.e., sequential, alternating, and maintenance/consolidation chemotherapy).2. Identify potential advantages and drawbacks of these new strategies in advanced NSCLC.3. Discuss the results of clinical trials testing sequential, alternating, and maintenance/consolidation chemotherapy in advanced NSCLC.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTA platinum-based doublet with a third-generation agent (paclitaxel, vinorelbine, gemcitabine, docetaxel) represents the standard first-line treatment for advanced nonsmall cell lung cancer patients with good performance status (PS). Traditional chemotherapy provides response rates of 20%-40% and a median survival of 8 -10 months.In an attempt to improve its outcome, alternative schedules have been proposed, namely sequential, alternating, and maintenance/consolidation therapy. Sequential chemotherapy with a platinum-based doublet followed by a single agent is feasible in patients with good PS; preliminary results from randomized phase III trials with combination chemotherapy as a comparator are promising, suggesting similar efficacy and a better toxicity profile for the sequential arm. The use of sequential single agents is an option for elderly and frail patients unsuitable for a platinum-based combination.Based on trials published so far, it is unlikely that an alternating chemotherapy strategy will be proven superior to standard chemotherapy in patients with good PS. However, sufficient evidence exists that it could be appropriate in the elderly or in unfit individuals.Consolidation/maintenance chemotherapy may provide additional benefit for patients achieving disease control after standard first-line chemotherapy. Better results are seen when maintenance consists of an agent that has proven active in the induction phase. Further evaluation of this strategy, as well as of consolidation/maintenance therapy with targeted agents, is warranted.In conclusion, these approaches may improve the out-

show abstract

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer

Cited by 22 publications

References 14 publications

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature

Contact Info

Product

Resources

About